TGEN director Hatsopoulos buys 10,000 shares at $0.84; stock down -24.1% from 52-week high, company unprofitable
Director Hatsopoulos purchased 10,000 shares at $0.84 on 2024-09-27, extending a recent pattern: he also bought 30,000 shares two days prior on 2024-09-25. The stock is currently trading at $0.82, down -24.1% from its 52-week high of $1.08 and down -21.2% over 30 days. Tecogen remains unprofitable with annual net income of $-1.5M against quarterly revenue of $4.7M, and full-year growth was minimal at +0.6%. His prior purchases at this ticker show mixed near-term results (30-day outcomes ranging from -13.5% to +29.2%), though the two completed 90-day windows both delivered gains (+31.2% and +35.0%). This buy occurs in a context of depressed valuations and continued operational losses.
Director John Hatsopoulos buys 10.0K shares of TGEN at $0.86 amid -24.1% 30-day decline, extending pattern of 5 buys within 4 months.
Hatsopoulos purchased 10,000 shares at $0.86 on 2024-09-25, bringing his holdings to 978,951 shares. This represents his fifth buy at TGEN in four months (prior buys on 2024-08-19, 2024-07-10, 2024-05-29, 2024-05-28, and 2024-05-24), executed at a price -24.1% from the 52-week high of $1.08. Of his three prior TGEN buys with measurable 90-day outcomes, all three showed positive 90-day returns (ranging from +31.2% to +35.0%). However, the current price of $0.82 is now 4.9% below this transaction's $0.86 entry, and the company remains unprofitable with $-1.5M net income against $4.7M quarterly revenue and only +0.6% annual revenue growth. The clustering of purchases and favorable historical 90-day outcomes at this ticker warrant monitoring of whether this pattern of accumulation near recent lows will again precede a recovery or signal diminishing returns.
Director John Hatsopoulos buys 10,000 TGEN shares at $0.90; company unprofitable with $-1.5M net income, stock +23.3% in 30 days.
Director John Hatsopoulos purchased 10,000 shares of Tecogen at $0.90 on 2024-08-19, increasing his holdings by 1.0% to 969.0K shares. The stock has appreciated 23.3% over the prior 30 days and currently trades at $0.92, down 22.7% from its 52-week high of $1.19. Across his cross-ticker track record, Hatsopoulos has achieved an 87.50% win rate over 90 days with an average 90-day return of 6.7%, though his five prior trades at Tecogen show mixed timing (1 of 1 measurable 90-day outcomes was well-timed). The company's fundamentals remain challenged: Tecogen posted $4.7M in revenue for the latest quarter while incurring $-1.5M in net income, with full-year net income negative and minimal annual revenue growth of 0.6%. This purchase occurs within a context of recent price momentum but persistent unprofitability.
Director Hatsopoulos buys 22,466 shares of TGEN at $0.65; holdings rise to 959.0K; stock down -47.6% from 52-week high.
Director John Hatsopoulos purchased 22,466 shares at $0.65 on 2024-07-10, increasing his holdings to 959.0K shares. This follows five other purchases at TGEN within the prior month—on 2024-05-21, 2024-05-22, 2024-05-24, 2024-05-28, and 2024-05-29—all of which have generated negative 30-day returns ranging from -5.6% to -13.5%. The stock currently trades at $0.66, down -47.6% from its 52-week high of $1.26, and has declined -7.9% over the past 30 days. The company is unprofitable, with net income of -$1.1M in the latest quarter and full-year net income negative. While Hatsopoulos's cross-ticker track record shows an 87.50% win rate with +4.7% average 90-day return on 20 prior buys, none of his five measured same-ticker purchases at TGEN have yet shown measurable 90-day outcomes, and all five visible 30-day periods post-purchase have been negative. The repeated accumulation despite consecutive losses and depressed valuation in a loss-making company presents a pattern worth monitoring.
